AP20187 (B/B Homodimerizer) is a cell-permeable compound used to dimerize FK506-binding protein (FKBP) fusion proteins, thereby initiating biological signaling cascades, gene expression, or disrupting protein-protein interactions.

Treatment of LNCaP cells with AP20187 (B/B Homodimerizer) at a concentration of 100 nM significantly reduces ro-iCaspase-9 levels, while the smaller, processed, active form of caspase-9 becomes evident.

Treatment with AP20187 significantly mitigates the effects of experimental autoimmune encephalomyelitis (EAE) on myelin sheaths in mice, markedly decreasing the prevalence of deteriorating axons and enhancing axonal density within demyelination sites in the lumbar spinal cord of PLP/Fv2E-PERK mice. Additionally, real-time PCR analysis reveals that AP20187 (B/B Homodimerizer) administration at doses of 0.5 mg/kg, 2 mg/kg, or 5 mg/kg notably elevates CHOP mRNA levels in the central nervous system (CNS) of PLP/Fv2E-PERK mice at post-infection day (PID) 12.